AGM Chair's address and CEO's presentation
Released
Released
Announcement PDF
ASX Announcement
AGM Chair Address and CEO Presentation
Melbourne, Australia; 26 November 2024: Starpharma (ASX: SPL, US OTC: SPHRY), an innovative
biotechnology company with two decades of experience in advancing dendrimer technology from the
lab to the patient, today provides a copy of the Chair’s address and CEO’s presentation for
shareholders at the Annual General Meeting (AGM) of Starpharma Holdings Limited, scheduled for
2:00 pm (Melbourne time) today.
About Starpharma
Starpharma ASX: SPL, US OTC: SPHRY) is an innovative biotechnology company with two decades of experience in advancing
dendrimer technology from the lab to the patient. Our mission is to help patients with significant illnesses, such as cancer, achieve
improved health outcomes and quality of life through the application of our unique dendrimer technology.
Dendrimers are precise, synthetically manufactured, nanoscale molecules. Their unique properties—including their size, structure,
high degree of branching, polyvalency, and water solubility—are advantageous in medical and pharmaceutical applications.
Starpharma’s portfolio of dendrimer-based products includes three clinical-stage DEP® (dendrimer enhanced product) assets,
preclinical radiopharmaceutical assets, research collaborations, and three commercially marketed over-the-counter (OTC) products.
For more information about Starpharma, visit www.starpharma.com or connect with Starpharma on LinkedIn.
WE Communications
Hannah Howlett
+61 450 648 064
WE-AUStarPharma@weworldwide.com
Starpharma Holdings Limited
Cheryl Maley, Chief Executive Officer
Justin Cahill, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067
Disclosure
This ASX Announcement was
authorised for release by the
Chair, Mr Rob Thomas.
Forward-Looking Statements
This document contains certain forward-looking statements, relating to Starpharma’s business, which can be identified by the use of forward-looking
terminology such as “promising”, “plans”, “anticipated”, “will”, “project”, “believe”, “forecast”, “expected”, “estimated”, “targeting”, “aiming”, “set to”,
“potential”, “seeking to”, “goal”, “could provide”, “intends”, “is being developed”, “could be”, “on track”, or similar expressions, or by express or implied
discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve
known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance
or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA’s
and other authorities’ requirements regarding any one or more product candidates, nor can there be any assurance that such product candidates will be
approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management’s expectations regarding
the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional
analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain
patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and
additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects.
Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from
those described herein as anticipated, believed, estimated, or expected. Starpharma is providing this information as of the date of this document and
does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or
developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not
necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or
reasonableness of future results. Nothing contained in this document, nor any information made available to you is, or shall be relied upon as, a promise,
representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.
Starpharma Holdings Limited
Annual General Meeting
26 November 2024
Chair’s Address to Shareholders
Good afternoon, fellow shareholders. Welcome to Starpharma’s 2024 Annual General Meeting.
On behalf of the Board of Directors, I want to thank you for joining us today and for your
continued support of Starpharma as shareholders.
Let me begin by reaffirming the Board and management team’s commitment to delivering results
and rebuilding value for all stakeholders. We fully understand the challenges posed by our
current share price and appreciate the patience of our long-standing shareholders. We
recognise the need for commercial success to restore investor confidence in our shares and are
working very hard to translate opportunities into tangible value creation.
This year has been one of significant transformation for our organisation. In January, Ms Cheryl
Maley assumed the role of Chief Executive Officer, bringing fresh perspectives and strategic
vision. I am pleased to report that the leadership transition has been seamless and that the
progress made in recent months under Cheryl’s leadership has been substantial.
As part of the CEO transition, we conducted a comprehensive review of the company’s
operations, spanning research and development, business development, and
commercialisation. This review has been instrumental in highlighting our strengths and
identifying opportunities to drive the company’s future success. While there have been
challenges, as is common in our sector, the robustness and potential of Starpharma’s
dendrimer technology have never been clearer.
Our strategy and objectives are now better defined, with transparency at the core of our
communications with shareholders and employees alike. The Board is confident that the
changes implemented this year will deliver ongoing benefits and support the long-term success
of the organisation.
Operational Highlights
Key achievements from the 2024 financial year include:
•
•
•
Recognition at ASCO: The Phase 2 results for Starpharma’s priority DEP® clinical assets,
DEP® SN38 and DEP® cabazitaxel, were presented at the American Society of Clinical
Oncology (ASCO) Annual Meeting in June. These presentations drew significant attention
to our dendrimer technology, with strong interest from companies and clinicians
regarding both the positive results and broader applications of DEP® in oncology.
Strategic Collaborations: The formation of Petalion Therapeutics in partnership with
Medicxi marked another milestone. This collaboration is dedicated to developing an
innovative cancer therapeutic leveraging Starpharma’s dendrimer technology, and early
results are encouraging. Cheryl will elaborate further on this and other partnerships in
her presentation.
Radiopharmaceuticals Progress: Starpharma advanced its DEP® radiopharmaceuticals
program and confirmed plans to initiate a first-in-patient clinical trial in 2025. The
2
company is completing the necessary optimisation research and preclinical activities to
ensure that any assets that advance to the clinic are poised to offer a competitive
advantage in the market.
Cheryl will soon deliver a detailed operational update during her presentation.
Addressing Challenges and Renewed Focus
While we celebrate these positive milestones, we also recognise that the recent updates
regarding Viraleze™ in Australia, VivaGel® BV in the US, and the AZD0466 partner program have
been disappointing. These setbacks are not expected to impact the company’s trajectory.
Instead, they have provided valuable insights that are shaping our strategic priorities and focus
moving forward.
Our renewed strategy emphasises securing a DEP® partner license and advancing our earlystage radiopharmaceuticals assets into the clinic. While Viraleze™ and VivaGel® BV remain
important for building longer-term sustainability through product sales, the true value and our
revenue potential lie in our DEP® oncology programs, which we anticipate will deliver substantial
growth in the coming years.
Looking Ahead
Over the next 12 months, our efforts will be centred on achieving key objectives to drive growth
and deliver value:
•
•
•
•
•
•
Securing Strategic Partnerships
Advancing Clinical Progress
Radiopharmaceutical Development
Product Launches
Boosting Revenue Streams
Team Development
These strategic priorities reflect our commitment to building a sustainable future for
Starpharma. The Board is confident that the actions we are taking today will position the
company for long-term success.
In addition, I want to highlight that all Board members have purchased shares on market this
year, underscoring our confidence in the Starpharma team and the unique value of our cuttingedge dendrimer technology.
Above all, we remain confident in the success of our mission to help patients with significant
illnesses, such as cancer, achieve improved health outcomes and quality of life through the
application of our unique dendrimer technology. Your continued support plays a vital role in
advancing these breakthroughs forward. It is very much appreciated.
Thank you.
Rob Thomas, AO
Chair
3
ASX : SPL
US OTC : SPHRY
Delivering Meaningful Patient
Outcomes with Advanced
Dendrimer Technology
Annual General Meeting | 26 November 2024
CEO, Cheryl Maley
Annual General Meeting 2024
2
Our Mission
Annual General Meeting 2024
“To help patients with significant
illnesses, such as cancer, achieve
improved health outcomes and quality
of life through the application of our
unique dendrimer technology.”
3
Disclaimer and Forward-Looking Statements
This presentation contains forward-looking statements that involve risks and uncertainties. Although we believe that the
expectations reflected in the forward-looking statements are reasonable at this time, Starpharma can give no assurance
that these expectations will prove to be correct. Actual results could differ materially from those anticipated. Reasons may
include risks associated with drug development and manufacture, risks inherent in the regulatory processes, delays in
clinical trials, risks associated with patent protection, future capital needs or other general risks or factors.
Annual General Meeting 2024
4
The Dendrimer
Platform Technology:
Clinically Validated,
Benefits Recognised
Annual General Meeting 2024
5
Starpharma – Founders and Experts in Dendrimer Drug
Delivery
Dendrimers are highly branched (tree-like) macromolecules with a well-defined, 3D structure
Dendrimer Generations
Cytotoxic
Ultra-toxic
Radioisotope
/ Chelator
Immunomodulator
G1
•
•
•
Annual General Meeting 2024
G2
G3
G4
Concentric layers of lysine monomers
Drugs, payloads, and/or targeting moieties attached via tailored linker strategies to achieve
enhanced tumour targeting and pharmacokinetics (PK)
Easily scalable, precisely manufactured, and Good Manufacturing Practice (GMP) certified
6
Starpharma’s Portfolio: Multiple Clinical-stage Assets,
Partnerships and Products In Market
Partnered DEP®
Programs
Internal DEP® Pipeline
Product
Target
indication
DEP® SN38
Ovarian and
colorectal
Phase II results reported
License/codevelop – ovarian,
colorectal
DEP® cabazitaxel
Prostate and
gastrooesophageal
Phase II results reported
License – prostate,
ovarian
Research
Preclinical
Phase I
Phase II
Phase III
Strategy
DEP® HER2
radiodiagnostic
Diagnostic
Optimise and
accelerate to
clinical
DEP® HER2
radiotherapeutic
Solid cancers
Advance to clinical
DEP® HER2 ADC
Solid cancers
Advance to
preclinical
DEP® docetaxel
Pancreatic
and other
cancers
Phase II results reported
Annual General Meeting 2024
SPL7013 Products on
Market
Lower priority
7
Annual General Meeting 2024
8
DEP® SN38 Phase I/II Trial Patients – Advanced, Heavily Pre-treated, and Most
CRC Patients had Progressed Following Prior Treatment with Irinotecan
Results Presented at the 2024 ASCO Annual Meeting
COLORECTAL
OVARIAN
PANCREATIC
BREAST
OTHER1
TOTAL
Subjects enrolled (n, %)
55 (48%)
23 (20%)
15 (13%)
8 (7%)
13 (11%)
114 (100%)
Subjects ongoing (n, %)
0 (0%)
1 (4%)
0 (0%)
0 (0%)
0 (0%)
1 (1%)
Median
(range)
59
(31-78)
64
(42-74)
65
(48-76)
53
(42-66)
60
(38-73)
61
(31-78)
Male
24 (44%)
0
8 (53%)
0
9 (69%)
41 (36%)
Female
31 (56%)
23 (100%)
7 (47%)
8 (100%)
4 (31%)
73 (64%)
0
23 (42%)
6 (26%)
6 (40%)
2 (25%)
-
40 (35%)
1
32 (58%)
17 (74%)
9 (60%)
6 (75%)
2
74 (65%)
III
2 (4%)
4 (17%)
0 (0%)
0 (0%)
2 (15%)
8 (7%)
IV
53 (96%)
19 (83%)
15 (100%)
8 (100%)
11 (85%)
106 (93%)
Irinotecan
54 (98%)
0 (0%)
11 (73%)
0 (0%)
3 (23%)
68 (60%)
Platinum
29 (53%)
23 (100%)
9 (60%)
0 (0%)
12 (92%)
73 (64%)
Taxanes
0 (0%)
23 (100%)
2 (13%)
7 (88%)
9 (69%)
41 (36%)
Median
(range)
4
(2-9)
6
(3 to 9)
2
(2 to 5)
7
(3 to 12)
3
(1 to 6)
4
(1 to 12)
BASELINE CHARACTERISTICS
Age (years)
Sex (n, %)
ECOG PS
Stage at diagnosis
Prior systemic therapy
(n, %)
Prior lines of therapy
1
Other cancer types included lung, upper gastrointestinal, and kidney.
Annual General Meeting 2024
9
DEP® SN38 Phase II Study Shows Favourable Efficacy and
Tolerability Data in Late-Stage Patients
Results Presented at the 2024 ASCO Annual Meeting
Advanced Colorectal Cancer
5
4.2
14
15
50%
4
2.8
3
10
2
5
45%
40%
4
35%
1
0
0
mPFS (months)
ORR (%)
Advanced Platinum-Resistant Ovarian Cancer
12
10.4
10
8
6
4
3.4
Gastrointestinal Toxicity Profile Significantly Improved with DEP®
SN38 Treatment, Compared to Published Data on Irinotecan#
50
43
25%
20%
30
5%
2
10
0
0
mPFS (months)
Annual General Meeting 2024
ORR (%)
DEP® SN38
Q3W
N=765
Q2W, Q3W
N=114
10%
0.90%
10%
0.90%
1.80%
0%
Diarrhea
≥Grade 3
47%
No cases of
cholinergic
symptoms
with DEP®
SN38
20%
15%
10%
11.8
Irinotecan
30%
40
20
Only 1 patient with
grade 3 diarrhoea
from 114 patients
and more than 800
doses of DEP® SN38
Vomiting
≥Grade 3
Nausea
≥Grade 3
0%
Cholinergic
Syndrome
Data for DEP® SN38 in combination with 5-FU/LV; Full Phase II results reported in ASX Announcement dated
27 May 2024; *From published data on irinotecan in combination with 5-FU/LV, Tournigand et al., Clin Oncol,
2023, 41(19):3469-3477; # https://www.medicines.org.uk/emc/product/6506- UK SmPC April 2022;
^From published data on ICC (investigator chemotherapy of choice) (pegylated liposomal doxorubicin,10
paclitaxel, or topotecan), Pujade-Lauraine E, et al., J Clin Oncol, 2014, 32(13):1302-1308
DEP® Cabazitaxel Phase I/II Trial Patients – Advanced, Heavily Pre-treated,
and Majority had Progressed Following Prior Taxane Therapy
Results Presented at the 2024 ASCO Annual Meeting
PROSTATE
OVARIAN
EGC
HNSCC
HEPATOBILIARY
OTHER*
TOTAL
25 (33%)
22 (29%)
15 (20%)
7 (9%)
4 (5%)
2 (3%)
75 (100%)
Median
(range)
73
(57-83)
62
(43-76)
61
(25 – 73)
60
(49-69)
65
(57-75)
73
(66-80)
65
(25-83)
Male
25 (100%)
0 (100%)
10 (67%)
6 (86%)
2 (50%)
1 (50%)
44 (59%)
Female
0 (0%)
22 (100%)
5 (33%)
1 (14%)
2 (50%)
1 (50%)
31 (41%)
0
15 (60%)
12 (55%)
8 (53.3%)
4 (57%)
2 (50%)
0
41 (55%)
1
10 (40%)
10 (45%)
7 (46.7%)
3 (43%)
2 (50%)
2 (100%)
34 (45%)
Median
(range)
4
(2-9)
4
(1-11)
1
(1-3)
3
(2-4)
2
(1-4)
3
(2-4)
3
(1-11)
Platinum
2 (8%)
22 (100%)
13 (87%)
7 (100%)
4 (100%)
2 (100%)
49 (65%)
Taxane
24 (96%)
22 (100%)
3 (20%)
4 (57%)
0 (0%)
1 (50%)
54 (72%)
Prior surgery (n, %)
Any
7 (28%)
21 (95%)
6 (40%)
3 (43%)
4 (100%)
2 (100%)
43 (57%)
Radiotherapy (n, %)
Any
21 (84%)
7 (32%)
6 (60%)
6 (86%)
2 (50%)
1 (50%)
46 (61%)
PATIENT BASELINE CHARACTERISTICS
Patients enrolled (n, %)
Age (years)
Sex (n, %)
ECOG PS
Prior lines of therapy
Prior systemic exposure
(n, %)
*lung and thymic carcinoma
Annual General Meeting 2024
11
DEP® Cabazitaxel Achieves Highly Encouraging Efficacy in LateStage Patients, Compared to Standard Therapies
Results Presented at the 2024 ASCO Annual Meeting
DEP® Cabazitaxel in Advanced Prostate Cancer
5
4
3
2
1
0
4.4
20
2.9
15
13.4
41.80%
14.7
10
DEP® cabazitaxel
N=5801
N=251
Low rates or absence of severe, dose-limiting bone
marrow toxicities in prostate cancer patients treated
with DEP® cabazitaxel, compared with Jevtana®
5
0
OS (months)
mPFS (months)
Jevtana^
DEP® Cabazitaxel in Advanced Gastro-Oesophageal Cancers
3
2.6
2
Paclitaxel2
4
10
4
8
6
4
1
2
0
0
mPFS (months)
6.7
16%
8.6
Paclitaxel2
5
OS (months)
2.10%
0%
2.60%
0%
2.10%
0%
Full Phase II results reported in ASX Announcement dated 18 October 2023;
*Lab detected neutropenia or thrombocytopenia, regardless of whether event was reported as
an adverse event; 1 Safety Population (received at least 1 dose); ^ Eisenberger, M, et al., J Clin
Oncol, 2017; 35(28):3198-206; 2 Stockton, S, et al., The Oncologist, 2023;28(9):827-e822.
Annual General Meeting 2024
12
Addressing the Biodistribution Challenges of Current
Approaches with DEP® Radiotheranostics
Starpharma’s DEP® Technology Solution:
Biodistribution Challenges
with Other Approaches:
Tumour:Blood ratio >40
30
DEP® HER2 radiodiagnostic: faster
clearance from blood and sustained
elevated tumour:blood ratios compared
to trastuzumab-89Zr
25
20
Tumour:Blood ratio >40
15
10
Bone
Colon
Lungs
Heart
Kidneys
Liver
0
Blood
5
Tumour
Low tumour uptake
%Injected dose/g
High kidney exposure
Tumour:Kidney/Organ
ratios highly positive
due to low uptake in
normal tissue
Spleen
Tumour:Kidney ratio highly negative
LHS Image from Lizak et al, 2024, SNMMI presentation – DLL3 RadioDARPin in tumor mouse model
Annual General Meeting 2024
13
Key Learnings from Partnerships
Dendrimer
technology offers
significant value
in drug
development
• Ability to modify the pharmacokinetics of drugs to suit
desired characteristics, including enhanced solubility
and widening the therapeutic window
• Applicable to a variety of therapeutic areas
• Patent extension
Companies want
solutions to
overcome drug
problems
• Medicxi selected Starpharma after a globe search for
experts in dendrimers to develop a specific drug for a
specific target
• Partner collaborations have facilitated new and
expanded partnerships with other companies
Evidence
generated by
Starpharma is
highly valued by
current and
prospective
partners
• Demonstrated proof-of-concept with extensive
preclinical and clinical data generated
• Partners have been able to achieve their desired
product profile with DEP® where other approaches
have not delivered the same benefits
Annual General Meeting 2024
AstraZeneca Case Study
➢ Demonstrated Starpharma’s
ability to:
o Expand the therapeutic
window of a toxic drug
by more than 20-fold
o Improve solubility
o Enable a toxic drug to
progress into human
trials for the first time
➢ Generated valuable
preclinical and clinical data
on the effectiveness of
Starpharma’s dendrimer
technology
14
Benefits of Starpharma’s DEP® Platform Technology Apply to a
Wide Range of Therapeutic Areas
Ability to use a wide range of targeting moieties
Site-specific attachment of dendrimer on targeting moiety
DEP® dendrimers are precisely manufactured and easily scalable
Drug-linker strategy flexibility
Flexibility in chelator type
Broad Applicability in
Drug Development
Annual General Meeting 2024
Can select drug payload and radioisotope for the desired application
Key
Characteristics
Valued by
Collaborators
Deep expertise in dendrimer science acquired over 20 years
15
The Commercial
Opportunity: Our
Strategy For Unlocking
SPL Value
Annual General Meeting 2024
16
Starpharma’s DEP® Platform Technology: Versatile and
Multifunctional for Delivery of Therapeutics and Diagnostics
Multiple Opportunities to Maximise Shareholder Returns
Phase II
Clinical
Assets
DEP® SN38 and DEP® cabazitaxel:
commercial opportunities to address
unmet needs in oncology
Rapidly
Emerging
Therapies
Strategic
Partnerships
Radiodiagnosis,
radiotherapy &
targeted
dendrimers
DEP
Platform
Novel therapy
areas & targets, &
new partnerships
Annual General Meeting 2024
Novel Areas of
Unmet Need
OTC
Products on
Market
VivaGel® BV, VIRALEZE Nasal Spray,
and VivaGel® Condom
17
Strategic Review in May Confirmed Three Key Focus Areas to
Optimise Shareholder Returns
01
02
03
Maximise DEP®
asset value
Accelerate early
asset
development
Build long-term
sustainability
Prioritising DEP® SN38 and DEP®
cabazitaxel
Advancing DEP®
radiopharmaceuticals and
partnerships
Annual General Meeting 2024
Increasing revenue,
strengthening IP position, and
fostering a high-performance
culture
18
Short- and Medium-Term Priorities Announced in May 2024
Significant Progress Made Across All Priorities Since May
Immediate
0 – 9 months
Our
Approach
Maximise DEP®
asset value
Accelerate
early asset
development
Build long-term
sustainability
Short
9 – 18 months
Medium
18 – 24 months
License DEP® asset/s
Radio and ADC Development
Radiotheranostic collaboration
Advance radiodiagnostic
New collaborations
New collaborations
Partner Milestones – MSD,
Genentech and Petalion
New target assets
New asset development
Viraleze UK & EU webstore
digital marketing
VivaGel® BV license
partnership
IP strategy review
Increase Viraleze webstore
sales
Sustainable income streams
Considered investment in
new candidates
Annual General Meeting 2024
19
Phase II
Clinical
Assets
®
Maximise DEP
DEP
Platform
Asset Value
Future
Opportunities
Annual General Meeting 2024
Rapidly
Emerging
Therapies
Strategic
Partnerships
OTC
Products on
Market
20
DEP® Clinical Assets Offer a De-risked Development Program
with an Established Market Opportunity
Chemotherapies remain standard-ofcare and form the backbone of
many cancer treatments
DEP® delivery improved anticancer
efficacy and tolerability in multiple
cancers in Phase II studies
Demonstrated ability to overcome
anticancer treatment resistance /
failure in patients previously treated
with the originator drug
Translation of preclinical findings
(pharmacokinetics, efficacy and
safety) to the clinic; GMP manufacture
Potential for a partner to leverage
accelerated development/regulatory
pathways (e.g., Fast Track, 505(b)(2))
Patent filings up to 2039, plus potential
for up to an additional ~5 years
Annual General Meeting 2024
21
DEP® SN38 & DEP® Cabazitaxel
Committed to Unlocking Global Commercial Opportunities
DEP® SN38
DEP® cabazitaxel
Starpharma has created value
through proof-of-concept and
is seeking to license both
products.
Partnering
Promising
Phase II Results
Value
Proposition
Both assets were developed
using the DEP® technology to
improve existing oncology
products.
Phase II studies for each asset
showed promising results of
improved tolerability over the
original compounds and
comparable or improved
efficacy. Trials have generated
promising anti-cancer efficacy
in very late-stage patients who
have been heavily pre-treated.
For a partner, both assets
provide opportunity for new
indications, new markets, and
product life cycle extension.
Annual General Meeting 2024
DEP® SN38 Phase II Results
Clinically meaningful outcomes were achieved for patients who
were heavily pre-treated prior to entering the trial and had few
options.
Promising efficacy in patients with irinotecan-treated CRC and
platinum-resistant/refractory ovarian cancer.
Well-tolerated with mostly mild/moderate gastrointestinal AEs, no
cholinergic toxicity.
DEP® cabazitaxel Phase II Results
Clinical benefit even in patients previously exposed to taxanes,
including standard cabazitaxel.
Promising efficacy in patients with mCRPC, ovarian and gastrooesophageal cancers.
Well-tolerated with mostly mild/moderate AEs, no routine steroid
premedication.
Indication Evaluation
Advanced
colorectal cancer
Platinum-resistant
ovarian cancer
Metastatic
castrationresistant prostate
cancer
Platinum-resistant
ovarian cancer
Advanced gastrooesophageal
cancer
22
We Have Made Significant Progress in 2024 in Our PartnerReadiness & Highly Focused Partner Engagement
Clinical &
Commercial
assessment:
Indications
prioritised
Phase
I/II results &
strategic
review
ASCO
presentations
/ meetings
Annual General Meeting 2024
Clinical
pathway and
regulatory
advice, tech
transfer
BD resources
increased,
extensive
partner
outreach &
engagement
License /
Research
Collaboration
agreement
23
Phase II
Clinical
Assets
Accelerate Early
Asset Development
DEP
Platform
Novel Areas
of Unmet
Need
Annual General Meeting 2024
Rapidly
Emerging
Therapies
Strategic
Partnerships
OTC
Products on
Market
24
Starpharma’s Proprietary DEP® Technology Has the Potential
to Address Limitations of a Wide Range of Diagnostics and
Therapies
DEP® Nano molecule
The Solution
The Problem
Despite advancements in medical
diagnosis and treatment, many
challenges remain. These include the
risk of misdiagnosis, poor drug
solubility, and toxic excipients in
formulations, all of which can
contribute to variability in patient
outcomes, unwanted side effects,
and a reduced quality of life for
patients.
Annual General Meeting 2024
Drug/Payload (e.g.,
Cytotoxic or Radioisotope)
/ Chelator
By applying Starpharma's DEP®
technology in developing diagnostics
and treatments, we aim to effectively
address these limitations. With our
technology, we can optimise
formulations, enhancing drug
solubility, and minimising toxic
excipients, ultimately leading to
better patient outcomes and an
improved quality of life.
25
Starpharma's Revitalised R&D Program to Support Accelerated
Pipeline & Go-No-Go Decisions
Process &
Governance
•Innovation, stage-gate
process, and project
management
People & Skill
Tools & Data
•Expand resources and
capability to match
targeted opportunities
•Efficiency in using global
data access, analytics,
and AI
Between 2016 and 2020, the average industry success rates for phase II and phase III were 29–34% and 70–73%,
respectively. The success rate for Phase I is significantly lower. Our goal is to leverage SPL’s and
industry experience and data to accelerate development and improve our success rate.
Annual General Meeting 2024
26
Creating Novel and Competitive Assets with Our Target
Product Profile for the DEP® Radiopharmaceutical Assets
Product Characteristics
• Real-time, accurate assessment of HER2+
tumour status (including low HER2+)
• Precise, total-body imaging of HER2+
tumours without the need for a biopsy
• Accurately informs treatment decisions
throughout the patient’s treatment journey
• Optimal timeframe for imaging for clinician
/ patient ease and reimbursement
• Simple manufacturing process
Annual General Meeting 2024
27
DEP® Radiopharmaceuticals Pathway to the Clinic
Targeting a First-in-Patient Clinical Trial in 2025
Estimated Timeline
Phase 1 commences
Diagnostic
Phase 1
results
Preclinical
Work
Complete
2H
CY2025
Phase 2 commences
1H
CY2026
Preclinical work
complete
2H
CY2026
Phase 1
commences
1H
CY2027
Phase 1 results
Radiotherapeutic
Annual General Meeting 2024
28
Phase II
Clinical
Assets
Accelerate Early
Asset Development
DEP
Platform
Novel Areas
of Unmet
Need
Annual General Meeting 2024
Rapidly
Emerging
Therapies
Strategic
Partnerships
OTC
Products on
Market
29
Extensive Partnership Experience, Multiple Opportunities for
Value Creation
Benefits of DEP® partnerships
• Leverage existing and create
new intellectual property
• Broaden the applications of
DEP®, creating multiple
potential revenue streams
Genentech
Partnership
MSD Research
Partnership
• Raise the profile of DEP®
• Revenue stream from R&D
services
Medicxi Collaboration
(Petalion Therapeutics)
Chase Sun
AstraZeneca
Overnight, AstraZeneca and
Starpharma have mutually agreed to
terminate their agreements.
Annual General Meeting 2024
30
Extensive Partnership Experience, Broad DEP® Application
Opportunity and a Flexible Approach to Collaboration
Current Partnerships
Types of Partnerships
and Collaborations
Progress with Expanding
Partnerships
•R&D collaborations
•Co-development
•License
•Technology access
•Multiple meetings and
CDAs with prospective
partners
•High engagement following
presentations at
conferences, including
ASCO
Applicable to a Wide Range of Therapeutic Areas
Annual General Meeting 2024
31
Developing an Innovative Cancer Therapy in Collaboration with
Medicxi, a Leading Healthcare Investment Firm
Assetcentric
approach
Revenue stream
from fee-for-service
development work
Ability to learn
and demonstrate
accelerated R&D
Annual General Meeting 2024
Novel asset
development
SPL receives 22.5% equity in Petalion in
exchange for licensing specific IP
SPL maintains background IP
Highly
experienced
team
Partner of
choice
32
Phase II
Clinical
Assets
Build Long-term
Sustainability
DEP
Platform
Novel Areas
of Unmet
Need
Annual General Meeting 2024
Rapidly
Emerging
Therapies
Strategic
Partnerships
OTC
Products on
Market
33
Maximise Revenue for VivaGel® BV and Viraleze Nasal Spray
Secure New Partners and Enhance Marketing
VivaGel® BV – a non-antibiotic topical
gel for the treatment of bacterial
vaginosis (BV) and prevention of
recurrent BV
Viraleze - a topical antiviral barrier
nasal spray for colds and respiratory
viruses, including coronaviruses
• Registered in 40+ jurisdictions, including in the
UK, Europe, Southeast Asia, Aust
Share your feedback
Discover